Daiichi Sankyo to close Japanese plant
This article was originally published in Scrip
Daiichi Sankyois to close a formulation plant in Osaka, Japan, operated by its Daiichi Sankyo Propharma subsidiary, as part of the restructuring of its domestic manufacturing operations. The decision followed a review of current and future capacity and product demand, and will see the facility's activities shifted to the firm's three remaining formulation sites in Japan or outsourced over the period to March 2011, when it will be closed. The Osaka site employs 130 people and makes Loxonin (loxoprofen) and Mevalotin (pravastatin) tablets, as well as an over-the-counter herbal digestive product. The impact of the move on earnings will be minor, Daiichi Sankyo said.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.